• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tiziana Life Sciences Ltd (NQ: TLSA )

    0.8461 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 115
    Open 0.8461
    Bid (Size) 0.8885 (2)
    Ask (Size) 0.9900 (7)
    Prev. Close 0.8461
    Today's Range 0.8461 - 0.8461
    52wk Range 0.4100 - 1.740
    Shares Outstanding 194,612,289
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tiziana Life Sciences Appoints New Chief Executive Officer
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire

    Performance

    YTD
    +48.41%
    +48.41%
    1 Month
    -25.78%
    -25.78%
    3 Month
    +17.51%
    +17.51%
    6 Month
    +72.67%
    +72.67%
    1 Year
    +24.79%
    +24.79%

    More News

    Read More
    The 3 Best EV Stocks to Buy in August 2024
    Via InvestorPlace
    Tiziana Life Sciences Granted FDA Fast Track Designation
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Receives $3.4 Million in Non-Dilutive Funding
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding
    Via News Direct
    Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
    Via FinancialNewsMedia
    Exposures Product Safety
    FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
    From FN Media Group LLC
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    EXCLUSIVE: Top Tesla Options Trades Recommended By Trading Expert
    Via Benzinga
    Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.